GleamWall
中文EN

MBX MBX Biosciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1776111 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-80.3%
TTM EPS YoY-139.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-33.7%
ROA-32.2%
ROIC (approx.)-53.3%
Asset turnover—

Leverage & solvency

Liabilities / assets5.5%
Debt / equity0.00x
Current ratio19.58x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.66x
Accruals ratio-10.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$32.05M$30.98M$18.47M$19.76M$19.27M$17.72M$22.41M$15.22M
SG&A expense$34.30M$9.95M$8.79M$6.04M$4.66M$4.08M$4.12M$3.39M
Operating income-$66.34M-$40.93M-$27.27M-$25.80M-$23.93M-$21.80M-$26.53M-$18.61M
Net income-$62.42M-$37.09M-$23.52M-$22.06M-$21.62M-$19.41M-$23.88M-$15.59M
EBITDA-$66.24M-$40.83M-$27.20M-$25.73M-$23.83M-$21.70M-$26.45M-$18.55M
EPS (basic)-1.29-0.78-0.50—-0.63-0.58-0.71—
EPS (diluted)-1.29-0.78-0.50—-0.63-0.58-0.71—
Weighted avg. shares (diluted)48.56M47.70M46.58M—34.20M33.45M33.41M—
Balance sheet
Cash & equivalents$161.69M$54.12M$45.21M$75.29M$223.12M$39.78M$29.90M$49.35M
Short-term investments$319.90M$364.46M$394.76M$298.42M$168.55M$185.12M$210.88M$212.80M
Current assets$492.76M$427.86M$448.54M$381.54M$397.50M$229.19M$244.28M$267.29M
PP&E, net$5.00M$4.66M$3.13M$2.73M$2.00M$1.73M$1.51M$1.08M
Total assets$500.62M$435.91M$452.70M$385.14M$400.08M$231.52M$245.93M$268.54M
Current liabilities$25.17M$23.66M$14.57M$15.49M$12.06M$11.76M$10.48M$11.05M
Total liabilities$27.67M$26.37M$14.95M$15.92M$12.54M$12.28M$10.50M$11.09M
Shareholders' equity$472.95M$409.54M$437.76M$369.22M$387.54M$219.24M$235.42M$257.44M
Shares outstanding49.64M47.95M47.57M44.93M44.72M33.59M33.42M33.42M
Cash flow statement
Operating cash flow-$34.88M-$22.62M-$20.21M-$18.30M-$21.54M-$17.43M-$22.68M-$16.04M
Capital expenditure$1.19M$901,000$437,000$793,000$399,000$707,000$30,000$92,000
Free cash flow-$36.07M-$23.52M-$20.64M-$19.09M-$21.93M-$18.14M-$22.71M-$16.13M
Investing cash flow$42.83M$29.21M-$97.10M-$129.97M$17.06M$25.99M$3.23M-$67.34M
Financing cash flow$99.61M$2.32M$87.44M$438,000$187.82M$1.33M$4,000-$132,000
Depreciation & amortization$100,000$100,000$64,000$60,000$100,000$100,000$77,000$58,000
Stock-based compensation$27.55M$6.06M$5.48M$2.66M$2.25M$1.94M$1.84M$1.49M

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.